These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide for the treatment of chronic graft-versus-host disease. Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151 [TBL] [Abstract][Full Text] [Related]
5. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
7. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281 [TBL] [Abstract][Full Text] [Related]
8. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671 [TBL] [Abstract][Full Text] [Related]
9. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919 [TBL] [Abstract][Full Text] [Related]
10. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303 [TBL] [Abstract][Full Text] [Related]
11. MC1288, a vitamin D analog, prevents acute graft-versus-host disease in rat bone marrow transplantation. Pakkala I; Taskinen E; Pakkala S; Räisänen-Sokolowski A Bone Marrow Transplant; 2001 Apr; 27(8):863-7. PubMed ID: 11477445 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
13. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Vogelsang GB; Hess AD; Gordon G; Santos GW Transplantation; 1986 May; 41(5):644-7. PubMed ID: 2939610 [TBL] [Abstract][Full Text] [Related]
19. Thalidomide responsive chronic pulmonary GVHD. Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183 [TBL] [Abstract][Full Text] [Related]
20. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]